Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANT GUARD
NCT06096337Active, not recruiting
- Sponsor
- Boston Scientific Corporation
- Start
- Dec 2023
- Primary completion
- Feb 2026
- Countries
- 13
01
Overview
Randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: Rate of device or procedure-related Composite Adverse Events that is serious at 12 months and Rate of intent to treat subjects with treatment success at 12 months. Started Dec 2023; status: active, not recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06096337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096337.